News

PaceMate Names JR Finkelmeier as Chief Commercial Officer

Former Philips Executive Joins to Accelerate Commercial Strategy and Market GrowthSARASOTA, Fla.--(BUSINESS WIRE)--PaceMate®, a market-leading cardiac remote monitoring and cardiac…

2 years ago

PaceMate Names JR Finkelmeier as Chief Commercial Officer

Former Philips Executive Joins to Accelerate Commercial Strategy and Market GrowthSARASOTA, Fla.--(BUSINESS WIRE)--PaceMate®, a market-leading cardiac remote monitoring and cardiac…

2 years ago

Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care

NORTHAMPTON, MA / ACCESSWIRE / May 14, 2024 / Olivia Sloan was pursuing a career in health policy and research…

2 years ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

Lecture to focus on engineering strategies applied to design safe and efficacious bispecific drug candidates, utilizing our proprietary platform technologiesSEATTLE,…

2 years ago

Jaguar Health Reports First Quarter 2024 Financial Results

The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net…

2 years ago

OSF HealthCare Joins MediLedger Network to Enhance Pricing Accuracy and Contract Management

PEORIA, IL / ACCESSWIRE / May 14, 2024 / OSF HealthCare, a health system in Illinois and Michigan, has joined…

2 years ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV

Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE /…

2 years ago

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile…

2 years ago

Revolo Biotherapeutics to Present at Upcoming Medical Meetings in May

GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, May 14, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company…

2 years ago

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to…

2 years ago